Anaplastic multiple myeloma with MYC rearrangement

Satoshi Ichikawa; Noriko Fukuhara; Ko Hashimoto; Fumiyoshi Fujishima; Ryo Ichinohasama; Hideo Harigae

doi:10.1016/j.lrr.2021.100288

Anaplastic multiple myeloma with MYC rearrangement

Leuk Res Rep. 2021 Dec 27:17:100288. doi: 10.1016/j.lrr.2021.100288. eCollection 2022.

Authors

Satoshi Ichikawa¹, Noriko Fukuhara¹, Ko Hashimoto², Fumiyoshi Fujishima³, Ryo Ichinohasama⁴, Hideo Harigae¹

Affiliations

¹ Department of Hematology, Tohoku University Hospital, Sendai, Japan.
² Department of Orthopaedic Surgery, Tohoku University Hospital, Sendai, Japan.
³ Department of Pathology, Tohoku University Hospital, Sendai, Japan.
⁴ Department of Hematopathology, Tohoku University Hospital, Sendai, Japan.

Abstract

A 52-year-old man with rapidly progressive paraplegia was presented to us with paravertebral tumors. Laminectomy with tumor resection was performed, and pathological analysis of the tumor revealed compact proliferation of anaplastic plasmacytoid cells. G-band analysis of the tumor revealed a complex karyotype, including IgH/MYC translocation. The patient was diagnosed with anaplastic multiple myeloma (AMM) with MYC arrangement, and cytotoxic chemotherapy followed by autologous hematopoietic stem cell transplantation resulted in long-term disease-free remission. This is the first report describing a case of de novo AMM with MYC rearrangement, suggesting that conventional chemotherapy could be a treatment option for this formidable disease.

Keywords: 1q21 aberration; Anaplastic multiple myeloma; Conventional chemotherapy; MYC rearrangement.

Publication types

Case Reports